ABSTRACT We present a retrospective review of DNA immunoadsorption (DNA-IA) therapy on clinical symptoms as well as indicators in pediatric cases with systemic lupus erythematosus (SLE), and follow up the short-term curative effects. 16 SLE cases were treated by DNA-IA for 3 times every other day. We observed the changes on clinical manifestations and immunological indicators, in order to compare the alteration of these indicators including clinical manifestations, Systemic Lupus Erythematosus Disease Active Index (SLEDAI) scores, 24 hurinary protein excretion, autoantibodies, serum IgG and complement C3. 13 cases were followed up regularly, within 3 months after DNA-IA therapy, 12 cases of clinical manifestations improved (92.3%). SLEDAI scores in 10 cases decreased from (16.20 ± 12.54) to less than 5 (76.9%), 8 cases of ANA, anti-DNA antibodies were negative (61.5%), 13 cases with IgG level in serum recovered to normal (10.39 ± 4.38) g/L, C3 level rose to normal (1.06 ± 0.23) g/L. 3 to 6 months after IA, clinical manifestations and laboratory examinations in all cases got maximum improved. 9 months after IA, SLEDAI score in 2 cases (15.4%) rose to more than 5, anti-DNA antibody in 2 cases (15.4%) became positive, and 1case (7.7%) with serum C3 decreased again. 2 cases died from multiple organs dysfunction within 3 to 6 months after IA. No serious complications were found during DNA-IA. We recommend that DNA immunoadsorption is a safe and effective therapy for active childhood-onset SLE, which could improve clinical symptoms, eliminate ANA and anti-DNA antibodies. Combining with corticosteroids and immunosuppressive drugs, DNA-IA could significantly reduce the activity of disease and protect vital organs function in the short term.
Cite this paper
Tang, X. , Zou, Z. , Zhao, X. , Chen, X. , Zhang, Y. and Li, Q. (2012) DNA immunoadsorption for childhood-onset systemic lupus erythematosus. Advances in Bioscience and Biotechnology, 3, 386-391. doi: 10.4236/abb.2012.34055.
 Xia, J.H. and Wu, HS. (1993) Anti-DNA antibodies in SLE pathogenesis significance. Shanghai Journal of Immunology, 13, 172-175．
 Terman, D.S., Buffaloe, G., Mattioli, C., et al. (1979) Extracorporeal immunoad-sorption: Initial experience in human systemic lupus erythematosus. Lancet, 2, 824-827.
 Stummvoll, G.H. (2011) Immunoadsorption (IAS) for sys- temic lupus erythematosus. Lupus February, 20, 115-119.
 Kihm, L.P. and Schwenger, V. (2011) Plasmapherese und immunadsorption auf der intensivstation. Der Nephrology, 6, 149-154.
 Kong, D.L., Schuett, W., Boeden, H.F., et al. (2000) Development of a DNA immunoadsorbent: coupling DNA on sepharose 4FF by an efficient activation method. Artificial Organs, 24, 845-851.
 Kong, D.L., Schuett, W., Dai, J., et al. (2002) Development of cellu-lose-DNA immunoadsorbent. Artificial Organs, 26, 200-208.
 Zuo, X.L., Tao, L.J. and Gao, J.S. (2006) Kelley’s text- book of rheumatology. 7th Edition, People’s Medical Publishing House, Beijing, 1362-1364.
 Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., McShane, D.J., Rothfield, N.F., et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism, 25, 1271-1277.
 Liu, X. and Wu, Y.B. (2008) The effect and safety of immunoadsorption therapy for children with severe systemic lupus erytheumtosus. Chinese Journal of Practical Pediatrics, 23,760-763.
 Willeke, P., Schlüter, B., Schotte, H., et al. (2004) Increased frequency of GM-CSF secreting PBMC in cases with active systemic lupus erythematosus can be reduced by immunoadsorption. Lupus, 13, 257-262.
 Willeke, P., Schotte, H., Erren, M., et al. (2002) Concomitant reduction of disease activity and IL-10 secreting peripheral blood mononuclear cells during immunoadsorption in cases with active systenic lupus erythematosus. Cell and Molecular Biology, 48, 323-329.
 Bosch, T. (1996) Current status in extracorporeal immunomodulation: Immune disorders. Artificial Organs, 20, 902-905. doi:10.1111/j.1525-1594.1996.tb04567.x